The company has established substantive cooperation with Pure Biologics S.A., a biopharmaceutical company. The two entities will cooperate in the field of research and development on biotechnological drugs, which will result in the identification of potential biotech drug candidates, which Celon Pharma will subsequently be developing in preclinical and clinical areas.
Maciej Wieczorek, PhD, CEO of Celon Pharma S.A.: We are consistently expanding our portfolio of innovative drugs, in which biotechnology drugs will play an increasingly important role. Our areas of interest are various classes of modified antibodies characterised by therapeutic potential in inflammatory diseases and other rare autoimmune diseases. We have also enhanced our team of researchers at our R&D Centre by welcoming new experts specialising in the development of biotech projects. We are convinced our cooperation with Pure Biologics will be smooth and fruitful.